TRAW Stock Forecast: Traws Pharma, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.18
−23.91% on the day

The median 12-month analyst price target for Traws Pharma, Inc. is $1. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 56 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$2.8M
Ticker Nerd rank
56/ 100
Median analyst target
$1.00
Analysts covering
2
Revenue$0.0−100.0% y/y
Operating income−$3.2M
Net income−$3.1M
Free cash flow−$7.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−30.0%
1M
−53.9%
YTD
−84.5%
1Y
−91.8%
From 52W high
−93.8%
From 52W low
0.0%
$0.18
$2.82
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Traws Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
56/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
90
Revisions
76
Growth
69
Quality
31
Volatility
30
Issuance
23
Momentum
23
Value
21

Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (21): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TRAW stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TRAW, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$0.50$1.00$1.50$2.00$2.50$3.00Jan 26Apr 26Jul 26Oct 26TRAWHigh $1.00Median $1.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
0
Buy
2
Hold
0
Sell
$1.00
Low
$1.00
Median
$1.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026HC Wainwright & Co.ReiteratesNeutral$1.00
18 June 2026HC Wainwright & Co.DowngradeNeutral$1.00
15 June 2026Ladenburg ThalmannDowngradeNeutral—
20 May 2026HC Wainwright & Co.ReiteratesBuy—
3 Dec 2025HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TRAW.

Market Radar

This page is one stock. Monday covers all of them.

TRAW appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TRAW vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Traws Pharma, Inc. returned −91.8% against +6.9% for the S&P 500, dividends included.

TRAW vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120140Jan 26Apr 26Jul 26Oct 26TRAWS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TRAW analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.0×

Cheaper than 66% of US stocks

Price / book
1.6×

Cheaper than 51% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−1845.8%

Higher than 1% of US stocks

Return on assets
−139.5%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Traws Pharma, Inc. has a market value of $2.8M and an enterprise value of $353K.

  • Revenue in the twelve months to 30 June 2026: $0.0. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$21.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$19.4M.

  • Shares outstanding: 15.3M.

  • Traws Pharma, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

TRAW and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TRAWTraws Pharma, Inc.$2.8M56
MBIOMustang Bio, Inc.$2.7M19
DRMADermata Therapeutics, Inc.$2.5M26
GRIGRI Bio, Inc.$2.4M24
REVBRevelation Biosciences, Inc.$2.4M14
ONCOOnconetix, Inc.$2.4M16
HCWBHCW Biologics Inc.$2.4M48

Take a look at TRAW’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Traws Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TRAW

What is the TRAW stock price forecast for 2026-2027?

The median 12-month analyst price target for Traws Pharma, Inc. is $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TRAW stock a buy right now?

Of the 2 analysts covering Traws Pharma, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Traws Pharma, Inc. 56 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TRAW?

As at 21 Nov 2026, Traws Pharma, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).

Will TRAW stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $1, and Ticker Nerd's factor model ranks Traws Pharma, Inc. 56 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TRAW stock forecast for 2030?

No analyst covering Traws Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRAW are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $1 over the next 12 months.

How has TRAW stock performed over the past year?

Traws Pharma, Inc. returned -91.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Traws Pharma, Inc. do?

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for respiratory viral diseases and cancer. Traws Pharma’s current pipeline centers on investigational antiviral and oncology programs, including candidates for influenza, COVID-19, bird flu, and certain cancers.

Company

About Traws Pharma, Inc.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for respiratory viral diseases and cancer. Traws Pharma’s current pipeline centers on investigational antiviral and oncology programs, including candidates for influenza, COVID-19, bird flu, and certain cancers. Its respiratory viral disease portfolio is designed to address treatment resistance and unmet medical needs in high-risk infections, while its oncology programs target solid tumors and hematological malignancies. The company’s work spans drug discovery, clinical development, and regulatory planning, with an emphasis on novel mechanisms of action and oral administration. Based in Newtown, Pennsylvania, Traws Pharma operates as a small-cap biotechnology name within the healthcare sector, where it contributes to the advancement of specialized therapies for serious diseases.

CEO Dr. Iain D. Dukes DPHIL, M.A., Ph.D. · 4 employees · United States · https://www.trawspharma.com